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Abstract: The exact role of FasL, and particularly its soluble and membrane-bound forms, in the development of
chronic ILDs and lung fibrosis has not been extensively explored. We aimed at analyzing membrane-bound FasL
expression on alveolar macrophages (AM) and lymphocytes (AL) as well as soluble FasL (sFasL) levels in bron-
choalveolar lavage (BAL) from ILDs patients, incl. pulmonary sarcoidosis (PS), hypersensitivity pneumonitis
(HP), silicosis, asbestosis, idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), and
healthy subjects (n = 89, 12, 7, 8, 23, 6, 17, respectively). In IPF, significantly increased percentage of AM FasL+
and CD8+FasL+ cells as well as sFasL levels in BAL were found. Increased sFasL levels were also observed in
HP. NSIP and asbestosis were characterized by higher AM FasL+ relative number; CD8+FasL+ population was
expanded in asbestosis only. There was a significant decline in AL FasL+ percentage in PS and HP. Vital capacity
was negatively correlated with sFasL levels, AM FasL+ and CD8+FasL+ cell relative count. CD4+FasL+ and
CD8+FasL+ percentage strongly correlated with BAL neutrophilia, an unfavorable prognostic factor in lung
fibrosis. The concurrent comparative BAL analysis of FasL expression indicates that FasL+ AM and AL (mainly
Tc cells) comprise an important element of the fibrotic process, mostly in IPF. FasL might play a crucial role in
other fibrosis-complicated ILDs, like NSIP and asbestosis. (Folia Histochemica et Cytobiologica 2011; Vol. 49,
No. 4, pp. 636–645)
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Introduction
The Fas/FasL system is considered to be the most ef-
ficient start point of the apoptosis extrinsic pathway,
and therefore plays a crucial role in the regulation of
cell death and survival [1]. It comprises Fas ligand
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(FasL, CD95L, CD178) and its cell surface membrane
receptor, Fas (FasR, CD95, APO-1). FasL is a pro-
tein existing both in a soluble (sFasL) and a cell mem-
brane-bound form. Fas is expressed as a member of
the tumor necrosis factor family of surface receptors;
binding of FasL to Fas results in apoptosis of suscep-
tible cells [2]. The process is particularly effective if
FasL molecules form trimers. The Fas/FasL system is
involved in the pathomechanisms of immunity and
inflammation, including lymphocyte-dependent cyto-
toxicity, alloreactive T cells clonal deletion, virally
infected or cancer cells removal as well as activation
induced cell death (AICD) of T lymphocytes [3, 4].
Elevated serum sFasL concentrations have been ob-
served in malignant and inflammatory diseases [5]. Fas
is expressed by multiple cell and tissue types, whereas
Fas Ligand is expressed mostly in activated T cells. It is
active as one of the major effector molecules in natu-
ral killer cells and cytotoxic T lymphocytes, in particu-
lar CD8 T cells, CD4 T helper 1 (Th1) cells [6]. Con-
sequently, in septic shock, the Fas/FasL system has been
regarded as a potential therapeutic target [2].
In airways, FasL involvement was first established
in the pathogenesis of acute lung injury (ALI). Mat-
ute-Bello et al. were the first to suggest in 1999 that
massive release of sFasL within the respiratory sys-
tem of ALI patients might trigger severe epithelial dam-
age characteristic for ARDS [7]. Since then, the essen-
tial role of the Fas/FasL pathway in the development of
lower airways apoptosis, with subsequent alveolar epi-
thelial injury in, has been well confirmed in experimen-
tal models of lung inflammation/injury with lpr (i.e. Fas
deficient) mice as well as in clinical studies with ALI
and ARDS patients [8–11].
In contrast, the significance of FasL in chronic low-
er airways disorders, like interstitial lung diseases
(ILDs), has not been extensively evaluated. Kuwano
et al. reported an increased concentration of sFasL
in BAL supernatants from patients with interstitial
pneumonia associated with collagen vascular diseas-
es (CVD-IP) and with bronchiolitis obliterans orga-
nizing pneumonia [12]. In IPF group, sFasL levels
were relatively higher, but the difference compared
to controls did not reach statistical significance. Nev-
ertheless, BAL sFasL level was proposed as a useful
decision marker for systemic corticosteroid therapy
in IPF and CVD-IP patients [13].
Recent studies have revealed that while both forms
of FasL, soluble and membrane-bound, are capable
of inducing the apoptotic process, sFasL has a rela-
tively weak pro-apoptotic effect and might actually
down-regulate the activity of membrane Fas recep-
tors [1, 14]. Thus, membrane-bound FasL expressed
on cytotoxic cells seems to be more active in apopto-
sis induction than expected, due to facilitated trimer-
ization of FasL molecules and more efficient Fas re-
ceptors ligation. In general, the role of FasL is poten-
tially much more complex. For instance, experimen-
tal models of lung allogeneic grafts have indicated Fas
ligand as a tool for immune suppression and toler-
ance [15].
Nevertheless, it is commonly accepted that chronic
inflammatory events in lower airways, occurring in
ILDs, may result in epithelial damage followed by
pathological reparation, fibroblast proliferation and
disseminated lung fibrosis. This process is triggered
by multiple proapoptotic factors, with Fas Ligand re-
garded as one of the most powerful [16]. The fatal
ILD complication, lung fibrosis, occurs as an irrevo-
cable consequence of idiopathic pulmonary fibrosis
(IPF), while in other ILD entities it is less frequent,
as in NSIP or pneumoconiosis, or quite uncommon,
as in Th1 lymphocyte-driven hypersensitivity pneu-
monitis and early pulmonary sarcoidosis [17–19].
Because of what is set out above, the present study
was designed to provide insight into the Fas ligand
(FasL) role in the pathomechanism of lung fibrosis in
ILDs. Both Fas ligand forms, soluble as well as mem-
brane-bound one, expressed by lower airways inflam-
matory cells, i.e. alveolar macrophages and lympho-
cytes, were analyzed in BAL material fairly represen-
tative of the local microenvironment of respiratory
airways. Though the FasL functional activity was as-
sessed indirectly, local expression was analyzed in the
context of clinical data, in particular lung function
tests and BAL cytoimmunological profile. We as-
sessed reciprocal correlations between parameters
characterizing FasL expression in BAL.
Material and methods
Study population. Bronchoalveolar lavage (BAL) was car-
ried out in 145 patients with ILDs, including pulmonary sar-
coidosis (PS; n = 89), hypersensitivity pneumonitis (HP;
n = 12), silicosis (n = 7), asbestosis (n = 8), IPF (n = 23) and
nonspecific interstitial pneumonia (NSIP; n = 6). PS and
IPF patients were additionally subdivided according to their
smoking status: 31 patients with PS and five with IPF were
smokers. Smoking individuals with other ILDs (silicosis,
asbestosis, HP and NSIP) were not enrolled into the study.
PS patients with ongoing oral corticosteroid therapy
(n = 9; prednisone 15–60 mp p.o. for at least three months),
were analyzed separately. Otherwise, there was no history
of previous systemic steroid or immune suppressive thera-
py in patients included in the study. BAL was performed
with the informed consent of all patients as part of the rou-
tine diagnostics (Bioethics Committee of Nicolaus Coper-
nicus University, approval no KR 116/2006).
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The diagnosis criteria of all examined subjects have been
described previously [20]. Newly-detected PS was confirmed
by typical clinical representation, a patient’s specific histol-
ogy (non-caseating granulomas in biopsy) and high resolu-
tion computer tomography (HRCT) findings [18]. PS pa-
tients were stratified according to conventional chest X-ray
staging. HP was diagnosed on the basis of clinical data, in-
cluding patient history with characteristic symptoms after
allergen exposure, detection of specific antibodies in serum,
typical presentation in HRCT) and results of lung function
tests. In some cases, HP diagnosis was confirmed by lung
biopsy. Pneumoconioses were diagnosed according to the
chest X-ray standards of the International Labor Organiza-
tion in subjects with professional or environmental expo-
sure to inorganic dust, silica or asbestos, proven by anam-
nesis and typical findings in BAL cytology (ferrugineous
bodies in asbestosis and silica dust light emission in polar-
ized optical microscopy in silicosis) [17]. The diagnosis of
IPF/UIP and NSIP was based on histological features, re-
spectively usual interstitial pneumonia, UIP, or nonspecific
interstitial pneumonia, NSIP, on lung biopsy. Pathologic
pertinent negative findings were considered, and other clin-
ical conditions associated with secondary UIP or NSIP ex-
cluded. In seven patients, the diagnosis of IPF was estab-
lished without a lung biopsy, according to the consensus
criteria of the American Thoracic Society and European
Respiratory Society [21].
The control group consisted of 17 subjects, nine non-
smokers and eight smokers, diagnosed for ILD, in whom
complete clinical investigation, including lung function tests,
chest X-rays and HRCT finally excluded lung pathology.
The control subjects did not present any signs of infection
or chronic lung disease and were not on corticosteroid or
any medication known as a potential ILD cause.
BAL performance. BAL cytology. BAL was performed acc.
to European Respiratory Society guidelines, as described
previously [22]. In brief, premedication with midazolam and
local upper airways anesthesia with 2% lidocaine was fol-
lowed by bronchofiberoscopy using an Olympus Bf20. The
right lung middle lobe or left lung lingula was lavaged alter-
natively with a volume of 200 ml NaCl 0.9% sterile solu-
tion, instilled sequentially with four 50 ml aliquots. Then,
BAL fluid fractions were retrieved by gentle suction, pooled,
filtered and immediately transported to the laboratory.
Fluid recovery was calculated as the percentage of in-
stilled volume [17, 23]. The total cell count, cell viability
(trypan blue exclusion test) and differential count of BAL
inflammatory cells were calculated, as described before [20].
Enzyme-linked immunosorbent assay (ELISA) in BAL su-
pernatants. Fas Ligand level measurement in BAL super-
natant was performed by ELISA using a commercial kit
(R&D, catalogue no DFL00) according to the manufactur-
er’s recommendations. The optical density was measured
at 450 nm using spectrophotometric reader Elx800 (Biotek
Instruments, Inc., USA). Fas Ligand concentration was ex-
pressed as pg/ml.
BAL immune cells phenotyping and flow cytometry (FC).
All BAL samples fulfilled the precise criteria of cytometric
material acquisition and analysis [23]. Direct three-color
typing was applied. In brief, BAL samples containing 50 μl
of cell suspension (2–10 × 106 cells/ml) were incubated with
saturating amounts of mouse, fluorochrome-conjugated
monoclonal antibodies (MoAbs) directed against human
superficial CD3, CD4, CD8, CD16, CD56, CD95 (Fas)
CD178 (FasL) and CD45 antigens, (Becton Dickinson Im-
munocytometry Systems, Serotec) for 30 min in the dark,
washed in PBS and resuspended in 300 μl of PBS with 1%
formaldehyde. Internal control consisted of samples not-
stained and stained with negative isotype control (BDIS
Tritest). Monoclonal set was alternatively modified for poor
lymphocyte samples. FC data was acquired within 24 hours
after staining, using argon ion laser 488 nm (FACSCalibur
and FACScan cytometers, BDIS). The emitted light was de-
tected through barrier filters specific for the emission range
of the fluorochromes used in the study: 530/22 nm (fluores-
cence channel FL1) for FITC, 585/42 nm (FL2) for PE and
> 650 nm (FL3) for PerCP. In each sample 8,000–12,000
cells were acquired. Alveolar macrophages (AM) and alve-
olar lymphocytes (AL) were gated according to cell granu-
larity (side scatter, SSC) and intensity of CD45 staining. AL
phenotype was yielded by dot plot quadrant analysis of re-
spective fluorescence channels. AM FasL+ percentage was
determined by window analysis of the additional sample
stained with MoAbs anti-CD178 PE/CD45 PerCP. The re-
sults were presented as the percentage of gated cells. Par-
ticulars are presented in Table 1 and Figure 1 [17, 20, 23].
Statistics. Patient age and lung function test results were
presented as mean ± SD, BAL phenotype and cytology re-
sults as a median ± SEM [23]. The Mann–Whitney U test
was used to compare the data obtained in analyzed groups
(untreated ILD patients vs. controls, smoker ILD subgroups
vs. respective nonsmokers, corticosteroid treated PS patients
vs. untreated ones). Spearman’s rank correlation coefficient
rs was applied to test the correlation between two random
variables; p values of less than 0.05 were considered statisti-
cally significant.
Results
The information about age, gender, lung function tests
and BAL fluid recovery in the nonsmoker groups, as
well as their BAL cytology data, is summarized in
Table 2. Since restrictive ventilation pattern is char-
acteristic for ILDs due to pulmonary fibrosis compli-
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Table 1. Monoclonal antibodies used for BAL cell typing in flow cytometry
Sample description FL1 FL2 FL3
Isotype control IgG1 FITC IgG1 PE Anti-CD45 PerCP
BD Pharmingen 340385 (Tritest)
CD3/NK Anti-CD3 FITC (Anti-CD16 and
–
Anti-CD56) PE
BD Pharmingen 340042
CD4/Fas/CD8 Anti-CD4 FITC Anti-CD178 PE Anti-CD8 PerCP
BD Pharmingen Serotec BD Pharmingen
345768 MCA 1539 347314
CD8/FasL/CD4 Anti-CD8 FITC Anti-CD95 PE Anti-CD4 PerCP
BD Pharmingen Serotec BD Pharmingen
345772 MCA 2409 555348
AM FasL Anti-CD178 PE Anti-CD45 PerCP
– Serotec BD Pharmingen
MCA 1539 345809
*For materials with AL < 5% of BAL leukocytes the following samples set was applied: Tritest, anti-CD3/NK/CD45,
anti-CD4(CD8)/FasL/CD45, anti-CD4(CD8)/Fas/CD45, anti-FasL/CD45 [23]
Figure 1. BAL flow cytometry. Principles of alveolar lymphocyte (AL) gating. FasL expression on AL. A. AL are gated as
dot plot R6 according to the side scatter (SSC) and CD45 expression. Attention should be focused on AM gating possible
in the same way (R5). Dots to the left of the marker are cellular debris. B. Back-gating. The major BAL cell populations
are redefined acc. to FSC/SSC parameters (R6 dots constitute R4 gate, i.e. AL dot plot). C. Coexpression of CD8 and
FasL on AL in PS patient: upper right quadrant dots are CD8+FasL+ cells (1.3% of AL). D. Coexpression of CD4 and Fas
Ligand on AL in NSIP patient: 7.1% of AL. Note the high number of dots in the upper left quadrant, representing mostly
CD8+FasL+ cells. All markers were set acc. to isotype negative control
cating their course, lung function analysis was limit-
ed to the vital capacity (VC) and diffuse lung capaci-
ty for carbon monoxide (DLCO) only, both present-
ed as a percentage of predicted values (% pred). Re-
markable alterations in both parameters were ob-
served in IPF and NSIP. A similar pattern, i.e. signif-
icantly impaired VC and DLCO, was present in smok-
ers with IPF compared to smoking controls; changes
in PS smokers were less pronounced. Corticosteroid-
-treated patients with PS (all nonsmokers, radiologi-
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cal stages II + III) presented significantly declined
VC values (data not shown).
BAL cytology results in the examined ILD groups,
including the impact of tobacco consumption on BAL
total cell count, cell composition, and CD4/CD8 in-
dex value, were typical for respective ILDs and con-
sistent with previously published data [17–20, 23–25].
In nonsmokers we managed to gather sFasL re-
sults in all ILD groups (Figure 2). IPF and HP pa-
tients exhibited significantly higher sFasL levels, 2.04 ±
± 2.28 pg/ml (p = 0.043) and 13.0 ± 7.6 pg/ml
(p = 0.019), respectively, compared to controls (0.21 ±
± 0.51 pg/ml). There were also relatively higher BAL
sFasL concentrations in NSIP subjects, though the dif-
ference did not reach statistical significance (p = 0.072).
Interestingly, sFasL levels observed in asbestosis were
considerably increased. The limited number of ana-
lyzed patients hardly allows any interpretation, sug-
gesting the need for further investigation.
Tobacco consumption resulted in a decline of
median sFasL level in IPF smokers, compared to re-
spective nonsmokers (p = 0.012). Corticosteroid ther-
apy did not seem to affect sFasL levels in sarcoidosis
patients: median values in PS stages II + III untreat-
ed and treated patients were similar.
AL immunotyping results are presented in Tables 3
and 4. Contrary to the common belief that CD8+
lymphocytes in the lower airways exhibit an exclusively
cytotoxic profile, a relatively high proportion of BAL
CD4+ cells expressed Fas Ligand, both in ILD pa-
tients and in controls. Moreover, while a remarkable
decline in the FasL+ lymphocyte relative count was
observed in HP and not-treated PS, CD8+FasL+ pro-
portion was significantly higher in asbestosis and non-
smoking IPF, compared to controls. It is worth not-
ing that in the corticosteroid treated PS group, con-
siderably higher FasL+ expression on AL and CD8+
cells in comparison with untreated PS was detected.
As a rule, the proportion of AM Fas Ligand+ was
enhanced in most analyzed ILD groups, i.e. in non-
smoking PS patients stages II + III, both steroid treat-
ed and untreated, in IPF and in NSIP (respectively,
43 ± 5.5%, 51 ± 14.8%, 48 ± 8.8% and 43.5 ± 12.3%
vs. 23 ± 13.6% in controls). A similar tendency,
though not statistically significant, was observed in
PS and IPF smokers in comparison with smoking con-
trols. The median values of FasL expression on AM
were significantly higher in IPF smokers than in re-
spective nonsmoking patients (Figure 3).
The analysis of FasL expression in the context of
selected clinical and BAL cytologic data is summa-
rized in Table 5. A significant negative correlation was
observed between VC % pred and sFasL level,
CD8+FasL+ cell, AM FasL+ as well as AL FasL+ rel-
641Fas Ligand (FasL) expression and lung fibrosis
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0087
www.fhc.viamedica.pl
Figure 2. Soluble FasL expression in BAL supernatants. The distribution of FasL levels in nonsmoking (panel A) and
smoking (panel B) subjects. Horizontal bars express median values. More particulars in the text; *p < 0.05 compared to
controls
Table 3. Nonsmokers’ FasL expression on alveolar lymphocytes (AL)
Group n CD4/CD8 [1] CD4+FasL+ (%) CD8+FasL+ (%) BAL lymphocytes
FasL+ (%)
PS I 24 9.7 ± 0.8≠ 4.8 ± 0.6 1.0 ± 0.3Ø 6.5 ± 0.8Ø
PS II + III 25 4.6 ± 0.9 ≠ 3.8 ± 1.0 1.7 ± 0.3 7.0 ± 1.6
PS total 49 8.6 ± 0.7≠ 4.3 ± 0.7 1.4 ± 0.3Ø 6.9 ± 0.9Ø
HP 7 1.1 ± 0.2Ø 2.5 ± 2.1 2.5 ± 1.7 4.5 ± 2.7Ø
Silicosis 7 1.8 ± 0.2 2.5 ± 0.9 4.1 ± 2.9 10.3 ± 3.3
Asbestosis 8 2.9 ± 0.7 9.3 ± 3.7 8.3 ± 1.3≠ 21.0 ± 5.8≠
IPF/UIP 18 1.2 ± 0.4Ø 4.5 ± 1.2 3.7 ± 0.8≠ 12.8 ± 1.5
NSIP 5 1.1 ± 0.5 7.3 ± 3.2 3.2 ± 0.8 13.7 ± 2.7
Controls 9 2.1 ± 0.5 5.3 ± 2.0 2.0 ± 0.8 9.6 ± 2.3
PS treated 9 2.7 ± 1.6 5.4 ± 1.0 5.8 ± 1.1 15 ± 2.4
(II + III)
Results presented as median ± SEM; ≠p < 0.05 increased; Øp < 0.05 decreased compared to controls; p < 0.05 increased; p < 0.05;
decreased compared to untreated PS II + III
ative counts. DLCO % pred correlated significantly
with soluble FasL concentration only. AL relative
count was positively strongly related to soluble FasL
levels and AM FasL+ percentage, while negatively to
CD8+FasL+ cells. BAL neutrophil relative count sig-
nificantly positively correlated with FasL expression
on both alveolar CD4+ and CD8+ cells, but not with
soluble FasL levels.
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Table 4. Smokers’ FasL expression on alveolar lymphocytes (AL)
Group n CD4/CD8 [1] CD4+FasL+ (%) CD8+FasL+ (%) BAL lym
phocytes FasL+ (%)
PS I 17 7.5 ± 1.0≠ 4.7 ± 0.7 1.6 ± 0.7Ø 8.2 ± 1.3Ø
PS II + III 14 3.1 ± 0.3≠ 4.9 ± 0.6 2.0 ± 0.7Ø 8.5 ± 2.1Ø
PS total 31 4.3 ± 0.6≠ 4.8 ± 0.5 2.0 ± 0.5Ø 8.0 ± 1.1Ø
IPF/UIP 5 0.9 ± 0.2 6.4 ± 1.6 8.2 ± 2.6 18.1 ± 3.3
Controls 8 0.9 ± 0.1 3.4 ± 1.3 7.3 ± 1.7 15.0 ± 2.6
Results presented as median ± SEM; ≠p < 0.05 increased; Øp < 0.05 decreased compared to controls
Figure 3. FasL expression on alveolar macrophages (AM). Percentage of positive AM. Results presented as medians of
resp. group; *p < 0.05 in comparison with controls
Table 5. Fas Ligand expression in lower airways versus selected clinical parameters and BAL cytology
Parameter VC DLCO AM AL Neutrophils
% pred % pred % of BAL cells % of BAL cells % of BAL cells
AM FasL+ (%) P 0.02 NS 0.01 0.05 NS
Rs –0.23 –0.20 +0.15
AL FasL+ (%) P 0.01 NS NS 0.02 0.0005
Rs –0.23 –0.17 +0.25
Th (CD4+) FasL+ (%) P NS NS NS NS 0.01
Rs +0.19
Tc (CD8+) FasL+ (%) P 0.003 NS 0.001 0.002 0.002
Rs –0.19 +0.24 –0.27 +0.22
Soluble FasL [pg/ml] P 0.008 0.03 0.000002 0.000003 0.06
Rs –0.27 –0.30 –0.40 +0.38 +0.16
P — probablity; Rs — Rank Spearman; AL — alveolar lymphocytes; AM — alveolar macrophages; Correlation results are presented for p < 0.10,
significant correlations (p < 0.05) are marked in bold
In Table 5 we do not show data demonstrating
excellent positive reciprocal correlations between
AM FasL+, AL CD4+FasL+ and AL CD8+FasL+
(p < 0.0000001 for all). This strongly suggests com-
mon powerful mechanisms underlying FasL expres-
sion on immune cells in ILD lower airways.
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We do not present particular results of AL typing
for NK cell marker (CD3–CD16+56+), CD3 and CD95
expression. Close to 100% of AL expressed CD95
without any significant differences. Similarly, both in
ILDs and controls, ~90% of AL were CD3+ with only
a few NK cells [17, 23]. AL T and NK cell count did
not correlate with lung function tests or FasL expres-
sion parameters.
Discussion
The close relationship between FasL and lung inju-
ry in acute lower airway disorders was proven long
ago [9]. Some evidence has suggested also a direct
link between pulmonary fibrosis and Fas Ligand ex-
pression in the lower airways. However, previously
published studies concentrated mostly on IPF and
collagen vascular diseases with concurrent ILD and
examined levels of soluble FasL only. Surprisingly,
patients’ smoking status and ongoing therapy were
not taken into account. Moreover, the examined
groups were too small to provide credible data for
statistical analysis. Still, Kuwano et al. were able to
demonstrate that IPF and CVD patients referred for
prednisolone therapy presented significantly higher
sFasL levels in BAL supernatants, compared to those
with a better prognosis and no indications to thera-
py [13]. Although the CVD group was not homoge-
nous and definite recommendations for systemic cor-
ticosteroid therapy in IPF have not been yet estab-
lished, the data presented by Kuwano et al. is of con-
siderable importance.
Nonetheless, to the best of our knowledge, the
current study is the first to provide simultaneous anal-
ysis of the membrane-bound and the soluble forms
of FasL in the BAL material from the wide range of
interstitial lung diseases with consideration to systemic
corticosteroid treatment and the smoking status of
the examined population.
The key finding presented here is the significantly
higher concentration of sFasL observed in BAL su-
pernatants of IPF and HP patients, with a tendency
towards it in NSIP. We are the first to report this phe-
nomenon in HP and NSIP groups, while data con-
cerning IPF patients is in line with previous reports
[13]. Not surprisingly, sFasL was not increased in sar-
coidosis, which is infrequently complicated by lung
fibrosis.
In our study, we suggest considerable FasL in-
volvement in the pathogenesis of asbestosis. But as
mentioned previously, a much larger group of pa-
tients needs to be evaluated in order to provide
credible data.
In our opinion, the significant negative correla-
tion between sFasL levels in BAL supernatants and
lung function tests characterizing restriction pattern
of ventilation disorders (VC % pred and DLCO
% pred), as well as the relationship between VC % pred
and membrane expression of FasL on AM and Tc cells
demonstrated in the study, are of considerable inter-
Figure 4. Correlation between sFasL expression in BAL supernatant and VC predicted value; p = 0.008; RS = –0.27
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est. But these results should be reevaluated in the
context of experimental data suggesting the complex
role of FasL in inflammatory processes. Thus, solu-
ble FasL levels might reflect the activation status of
immune cells rather than the local pro-apoptotic ca-
pacity [3]. As mentioned above, the membrane-bound
FasL form is potentially more efficient in triggering
apoptosis of target cells than the soluble one. Such
conclusions are supported by our results collected in
smokers with IPF and corticosteroid treated PS pa-
tients. In the IPF smoker group, sFasL levels were
comparable to the results detected in nonsmoking
patients. Furthermore, while in many BAL samples
of IPF smoking patients, sFasL concentration was
undetectable, it is well known that there is a high risk
of extremely unfavorable disease outcome in smok-
ers [19]. In corticosteroid treated PS, contrary to our
expectations, soluble FasL levels were not lower than
in untreated counterparts.
Thus, the results presented in our study seem to
disagree, at least to a certain extent, with the theoret-
ical model of FasL pathogenetic role in IPF and oth-
er ILDs. Still, hypothetically, FasL+ immune cells,
including alveolar T cells, in particular T cytotoxic
cells and alveolar macrophages, might comprise the
most powerful pro-apoptotic and/or cytotoxic com-
ponent of the FasL system expressed in lower airways.
To the best of our knowledge, our study is the first to
provide compelling analysis of FasL expression in AM
population. Interestingly, experimental data seems to
substantiate considerable AM pro-apoptotic activity
against respiratory epithelia, higher than in other in-
flammatory cells [26]. According to our results, AM
FasL+ subpopulation was significantly increased in
IPF (in particular in smokers, an IPF subgroup with
an extremely poor prognosis), NSIP and stages II–III
both treated and untreated PS patients.
In our study ILD entities characterized by Th1
prevalence and lymphocytic alveolitis, as HP and un-
treated PS, presented decreased FasL expression on
alveolar Th and Tc cells. A strong correlation between
sFasL levels and AL relative count was also observed.
Therefore, we believe that the relationship between
sFasL expression and BAL lymphocyte accumulation
reported in some studies might reflect FasL shedding
from the AL membrane rather than the direct im-
pact of FasL on lymphocyte recruitment [1, 9]. Addi-
tionally, in our data, the highest proportion of AL
FasL+ was shown in IPF (for CD8) and asbestosis (for
both CD8 and total AL). Also, PS patients on corti-
costeroid therapy (usually due to threatening lung fi-
brosis) presented higher AL FasL expression com-
pared to untreated PS. The VC % pred values corre-
lated negatively with both AM FasL+ and Tc FasL+.
Consequently, we suggest that FasL+ expression on
alveolar lymphocytes and macrophages might reflect
pro-apoptotic potential of local immune reaction,
decisive for subsequent progression to lung fibrosis.
This concept is nicely supported by the strong cor-
relation between FasL expression on AL, both CD4+
and CD8+, and BAL neutrophil relative count dem-
onstrated in our study. It is consistent with some pre-
vious reports of neutrophil recruitment by Fas Ligand
to the inflammation site [27]. It has been shown as
well that membrane-bound FasL could induce neu-
trophil infiltration in mice. Thus, FasL chemotactic
activity towards human and murine neutrophils has
been implicated, though the detailed mechanism re-
mains uncertain [2]. Consequently, the correlation
between BAL neutrophil number and FasL expres-
sion is an intriguing finding, as BAL neutrophilia, in
contrast to lymphocytosis, is an important unfavorable
prognostic factor in ILDs [17, 19, 28]. Our observa-
tions certainly require further investigation. However,
they are important due to the possible practical appli-
cations [29]. Quite recently, Chung et al. proposed the
inhibition of the Fas/FasL system as a successful treat-
ment against septic shock. The rationale of such an
approach was to block the excess of lymphocyte loss,
and to limit neutrophil accumulation [30].
In conclusion, it is worth emphasizing that our
study provides compelling data demonstrating the
upregulation of all FasL system components in IPF.
However, we believe that the pathogenic role of FasL
in other fibrosis-complicated ILDs, such as NSIP, as-
bestosis and advanced pulmonary sarcoidosis, is very
likely as well. Most importantly, we provide data
showing that tobacco consumption negatively affects
sFasL soluble levels, but does not diminish the rate
of sFasL+ inflammatory cells in BAL. Finally, the
presented results accentuate the potential role of
FasL+ alveolar lymphocytes and macrophages in
Fas-dependent triggering of epithelial apoptosis and
lung fibrosis, as well as suggesting that neutrophils
and FasL+ cytotoxic lymphocytes may act as triggers
of lung fibrosis in ILDs.
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